- Home
- AMGN vs HSBC Comparison
AMGN vs HSBC Comparison
Compare AMGN & HSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- HSBC
- Stock Information
- Founded
- AMGN 1980
- HSBC 1865
- Country
- AMGN United States
- HSBC United Kingdom
- Employees
- AMGN N/A
- HSBC N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- HSBC Savings Institutions
- Sector
- AMGN Health Care
- HSBC Finance
- Exchange
- AMGN Nasdaq
- HSBC Nasdaq
- Market Cap
- AMGN 147.3B
- HSBC 172.6B
- IPO Year
- AMGN N/A
- HSBC N/A
- Fundamental
- Price
- AMGN $263.38
- HSBC $48.29
- Analyst Decision
- AMGN Buy
- HSBC Hold
- Analyst Count
- AMGN 22
- HSBC 1
- Target Price
- AMGN $329.05
- HSBC N/A
- AVG Volume (30 Days)
- AMGN 4.7M
- HSBC 1.0M
- Earning Date
- AMGN 02-04-2025
- HSBC 10-29-2024
- Dividend Yield
- AMGN 3.62%
- HSBC 4.14%
- EPS Growth
- AMGN N/A
- HSBC N/A
- EPS
- AMGN 7.83
- HSBC 1.20
- Revenue
- AMGN $32,534,000,000.00
- HSBC $57,970,000,000.00
- Revenue This Year
- AMGN $20.04
- HSBC N/A
- Revenue Next Year
- AMGN $3.41
- HSBC N/A
- P/E Ratio
- AMGN $33.62
- HSBC $7.51
- Revenue Growth
- AMGN 21.25
- HSBC N/A
- 52 Week Low
- AMGN $253.30
- HSBC $36.93
- 52 Week High
- AMGN $346.85
- HSBC $49.18
- Technical
- Relative Strength Index (RSI)
- AMGN 31.29
- HSBC 60.77
- Support Level
- AMGN $253.30
- HSBC $47.84
- Resistance Level
- AMGN $280.00
- HSBC $49.18
- Average True Range (ATR)
- AMGN 5.95
- HSBC 0.49
- MACD
- AMGN -0.21
- HSBC -0.03
- Stochastic Oscillator
- AMGN 35.90
- HSBC 52.41
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in around 60 countries with around 220,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.